Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy

Sun,Ke‑Kang; Yang,Yang; Zhao,Lin; Wang,Li‑Li; Jiao,Yang

doi:10.3892/ol.2012.969

Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy

Authors:
- Ke‑Kang Sun
- Yang Yang
- Lin Zhao
- Li‑Li Wang
- Yang Jiao
View Affiliations

Affiliations: Department of Gastrointestinal Surgery Division of Thoracic Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu 215300, P.R. China, Key Laboratory of Radiation Biology, School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China
Published online on: October 15, 2012 https://doi.org/10.3892/ol.2012.969
Pages: 373-377

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti‑EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI‑H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib‑induced cell‑proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib‑induced anti‑proliferative cell cycle arrest.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 2:69–90. 2011. View Article : Google Scholar
2	Inamura K and Ishikawa Y: Lung cancer progression and metastasis from the prognostic point of view. Clin Exp Metastasis. 6:389–397. 2010. View Article : Google Scholar : PubMed/NCBI
3	Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:5749–5754. 2002.PubMed/NCBI
4	Ciardiello F: Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol. 1:221–234. 2005. View Article : Google Scholar : PubMed/NCBI
5	Maione P, Gridelli C, Troiani T, et al: Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 11:274–284. 2006. View Article : Google Scholar : PubMed/NCBI
6	Polychronis A, Sinnett HD, Hadjiminas D, et al: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growt h-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 6:383–391. 2005. View Article : Google Scholar
7	Montemurro F, Valabrega G and Aglietta M: Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther. 7:257–268. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 20:2240–2250. 2002. View Article : Google Scholar
9	Krol J, Francis RE, Albergaria A, et al: The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 6:3169–3179. 2007. View Article : Google Scholar : PubMed/NCBI
10	Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, et al: Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene. 4:705–713. 1996.PubMed/NCBI
11	Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 1:66–72. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang XM, Gao X, Zhang XH, et al: The negative cell cycle regulator, Tob (transducer of ErbB-2), is involved in motor skill learning. Biochem Biophys Res Commun. 4:1023–1027. 2006. View Article : Google Scholar : PubMed/NCBI
13	Jia S and Meng A: Tob genes in development and homeostasis. Dev Dyn. 4:913–921. 2007. View Article : Google Scholar : PubMed/NCBI
14	Helms MW, Kemming D, Contag CH, et al: TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Cancer Res. 12:5049–5056. 2009. View Article : Google Scholar : PubMed/NCBI
15	Jiao Y, Sun KK, Zhao L, et al: Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin. 33:250–260. 2012. View Article : Google Scholar : PubMed/NCBI
16	Astsaturov I, Cohen RB and Harari P: Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 6:1179–1193. 2006. View Article : Google Scholar : PubMed/NCBI
17	Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
18	Johnston JB, Navaratnam S, Pitz MW, et al: Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 13:3483–3492. 2006. View Article : Google Scholar : PubMed/NCBI
19	Uchida A, Hirano S, Kitao H, et al: Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 98:357–363. 2007. View Article : Google Scholar : PubMed/NCBI
20	Iwanaga K, Sueoka N, Sato A, et al: Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer. Cancer Lett. 1:71–79. 2003. View Article : Google Scholar : PubMed/NCBI
21	Ito Y, Suzuki T, Yoshida H, et al: Phosphorylation and inactivation of Tob contributes to the progression of papillary carcinoma of the thyroid. Cancer Lett. 2:237–242. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yanagie H, Tanabe T, Sumimoto H, et al: Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model. Biomed Pharmacother. 4:275–286. 2009. View Article : Google Scholar : PubMed/NCBI
23	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI
24	Felsher DW: Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer. 3:375–380. 2003. View Article : Google Scholar : PubMed/NCBI
25	Suzuki T, K-Tsuzuku J, Ajima R, et al: Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev. 11:1356–1370. 2002. View Article : Google Scholar : PubMed/NCBI